IE38568L - Oxaprostaglandins - Google Patents
OxaprostaglandinsInfo
- Publication number
- IE38568L IE38568L IE730881A IE88173A IE38568L IE 38568 L IE38568 L IE 38568L IE 730881 A IE730881 A IE 730881A IE 88173 A IE88173 A IE 88173A IE 38568 L IE38568 L IE 38568L
- Authority
- IE
- Ireland
- Prior art keywords
- formula
- prostaglandins
- compounds
- oxo
- single bond
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 abstract 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003301 hydrolyzing effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 150000004675 formic acid derivatives Chemical class 0.000 abstract 1
- 238000005984 hydrogenation reaction Methods 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1440601 Prostaglandins PFIZER Inc 30 May 1973 [2 June 1972 30 April 1973] 25846/73 Heading C2C The invention comprises prostaglandins of the formulµ wherein R is H or C 1-3 alkyl; W is a single bond or a cis double bond; Z is a single bond or a trans double bond; M is oxo, X and Y when taken together form a single bond or X is α-hydroxy when Y is H; n is 0, 1 or 2 and m is 0 to 4, and wherein M, X and Y are so selected as to complete the structure of a prostaglandin of the A, E or F series; and M<SP>1</SP> is oxo or and the pharmaceutically acceptable salts and the formates, akanoates and benzoates of the prostaglandins of Formula I. The PGA derivatives of the above formula are prepared by dehydrating the corresponding PGE compounds, obtained by hydrolysing the corresponding 11,15-bistetrahydropyranyl ethers of Formula II above in which M<SP>1</SP> is oxo, which are made by oxidizing the corresponding compounds of Formula II in which M<SP>1</SP> is The PGF compounds of Formula I are obtained either by reducing the corresponding PGE compounds of Formula I or by hydrolysing the corresponding 11,15 - bistetrahydropyranyl ether of Formula II in which M<SP>1</SP> is which are prepared by reacting ylides of the formula with lactals of the formula followed by, if desired, hydrogenation. Pharmaceutical compositions, suitable for oral, parenteral, topical, intranasal or intravaginal administration, contain the above prostaglandins of Formula I or pharmaceutically acceptable salts thereof together with suitable carriers or diluents. The compounds possess the same physiological activities as those exhibited by the natural prostaglandins. Reference has been directed by the Comptroller to Specification 1,345,934.
[GB1440601A]
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE1958/76A IE38570B1 (en) | 1972-06-02 | 1973-06-01 | Alkyl phosphonates |
| IE1957/76A IE38569B1 (en) | 1972-06-02 | 1973-06-01 | Cyclopentane derivatives |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25921572A | 1972-06-02 | 1972-06-02 | |
| US05/355,644 US4094899A (en) | 1972-06-02 | 1973-04-30 | Oxaprostaglandins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE38568L true IE38568L (en) | 1973-12-02 |
| IE38568B1 IE38568B1 (en) | 1978-04-12 |
Family
ID=26947161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE881/73A IE38568B1 (en) | 1972-06-02 | 1973-06-01 | Oxaprostaglandins |
Country Status (19)
| Country | Link |
|---|---|
| JP (3) | JPS5314062B2 (en) |
| AR (2) | AR199300A1 (en) |
| CA (1) | CA1095034A (en) |
| CH (3) | CH590224A5 (en) |
| DD (2) | DD109859A5 (en) |
| DE (2) | DE2344838C3 (en) |
| DK (1) | DK143498C (en) |
| ES (2) | ES441003A1 (en) |
| FI (1) | FI55995C (en) |
| GB (3) | GB1440603A (en) |
| IE (1) | IE38568B1 (en) |
| IL (2) | IL42373A (en) |
| IN (1) | IN138739B (en) |
| LU (1) | LU67738A1 (en) |
| NL (1) | NL162902C (en) |
| NO (1) | NO145438C (en) |
| PH (3) | PH11300A (en) |
| SE (4) | SE415756B (en) |
| YU (1) | YU36497B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES416865A1 (en) * | 1972-07-13 | 1976-03-01 | Pfizer | 15-substituted-omega-pentanorprostaglandins |
| US11756356B2 (en) | 2019-08-28 | 2023-09-12 | Igloocompany Pte. Ltd. | System and method for controlling multiple locks |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3538120A (en) * | 1967-05-22 | 1970-11-03 | Ciba Geigy Corp | Cyclopentyl-alkanoic acids |
| ZA721159B (en) * | 1971-03-22 | 1972-12-27 | Ici Ltd | Process for the separation of the c-15 epimers of 20-ethyl-9a,11alpha,15-trihydroxy-5-cis-13-trans-prostadienoic acid |
-
1973
- 1973-05-28 IL IL42373A patent/IL42373A/en unknown
- 1973-05-28 SE SE7307521A patent/SE415756B/en unknown
- 1973-05-28 IL IL7350311A patent/IL50311A/en unknown
- 1973-05-29 FI FI1735/73A patent/FI55995C/en active
- 1973-05-30 IN IN1265/CAL/73A patent/IN138739B/en unknown
- 1973-05-30 GB GB2306775A patent/GB1440603A/en not_active Expired
- 1973-05-30 GB GB2306575A patent/GB1440602A/en not_active Expired
- 1973-05-30 GB GB2584673A patent/GB1440601A/en not_active Expired
- 1973-06-01 DE DE2344838A patent/DE2344838C3/en not_active Expired
- 1973-06-01 CH CH797573A patent/CH590224A5/xx not_active IP Right Cessation
- 1973-06-01 DE DE2327813A patent/DE2327813A1/en not_active Withdrawn
- 1973-06-01 CH CH415576A patent/CH586716A5/xx not_active IP Right Cessation
- 1973-06-01 CH CH415476A patent/CH589074A5/xx not_active IP Right Cessation
- 1973-06-01 DK DK303973A patent/DK143498C/en not_active IP Right Cessation
- 1973-06-01 CA CA173,035A patent/CA1095034A/en not_active Expired
- 1973-06-01 IE IE881/73A patent/IE38568B1/en unknown
- 1973-06-02 JP JP6244973A patent/JPS5314062B2/ja not_active Expired
- 1973-06-04 PH PH14690A patent/PH11300A/en unknown
- 1973-06-04 YU YU01469/73A patent/YU36497B/en unknown
- 1973-06-04 DD DD171300A patent/DD109859A5/xx unknown
- 1973-06-04 LU LU67738A patent/LU67738A1/xx unknown
- 1973-06-04 DD DD182818A patent/DD124594A5/xx unknown
- 1973-06-04 AR AR248400A patent/AR199300A1/en active
- 1973-06-04 NL NL7307740.A patent/NL162902C/en not_active IP Right Cessation
-
1974
- 1974-01-29 AR AR252103A patent/AR203386A1/en active
- 1974-03-11 NO NO740849A patent/NO145438C/en unknown
-
1975
- 1975-04-07 PH PH17030A patent/PH12035A/en unknown
- 1975-04-07 PH PH17029A patent/PH11931A/en unknown
- 1975-09-16 ES ES441003A patent/ES441003A1/en not_active Expired
- 1975-09-16 ES ES441002A patent/ES441002A1/en not_active Expired
-
1976
- 1976-07-19 SE SE7608222A patent/SE7608222L/en unknown
- 1976-07-19 SE SE7608221A patent/SE418857B/en unknown
- 1976-07-19 SE SE7608223A patent/SE7608223L/en not_active Application Discontinuation
- 1976-09-08 JP JP51107650A patent/JPS5239629A/en active Pending
- 1976-09-08 JP JP51107651A patent/JPS5231054A/en active Granted
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1515414A (en) | 2 descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-omega-pentanorprostaglandins | |
| GB1373461A (en) | Tetrazoyl derivatives of naturally occuring prostaglandins | |
| SE7612262L (en) | KETOPHOSPHONATE INTERMEDIATE PRODUCTS AND PROCEDURES | |
| GB1450960A (en) | Stabilization of prostaglandins | |
| IE40977L (en) | Prostaglandin compositions | |
| IE38568L (en) | Oxaprostaglandins | |
| IE37909L (en) | Prostaglandin analogues | |
| GB1506822A (en) | Prostaglandins | |
| GB1506817A (en) | Prostaglandins | |
| IE39686L (en) | p-BIPHENYLYL ESTERS OF 15- SUBSTITUTED -16, 17, 18, 19 ,20-¹PENTANORPROSTAGLANDINS | |
| GB1396206A (en) | Prostaglandins and the preparation thereof | |
| GB1398291A (en) | Prostaglandin analogues and production thereof | |
| GB1361863A (en) | Piperazine derivatives their preparation and pharmaceutical compositions containing them | |
| GB1430995A (en) | 13-cis-prostaglandin derivatives and their preparation | |
| GB1373878A (en) | Prostaglandins and the preparation thereof | |
| ES418575A1 (en) | Difluoromethylene substituted prostaglandin derivatives | |
| GB1438093A (en) | Prostaglandins and the manufacture thereof | |
| JPS52138580A (en) | Cyclodextrin derivatives | |
| GB1480286A (en) | 11-substituted-11-deoxy-pge analogues | |
| GB1464205A (en) | Prostaglandins | |
| GB1398346A (en) | Prostaglandins and the preparation thereof | |
| GB1445628A (en) | Prostaglandin derivatives | |
| GB1456040A (en) | Prostaglandin 5-indanyl esters | |
| GB1362955A (en) | Omega - homo - prostaglandin e1 heptyl ester and production thereof | |
| GB1494321A (en) | Prostanoic acid derivatives |